Spironolactone-Associated Gynecomastia Management
Spironolactone can cause drug-induced gynecomastia through antiandrogenic effects that increase the estrogen-to-androgen effect in breast tissue. [2] Management consists of confirming the diagnosis, excluding malignancy, addressing reversible causes by modifying the offending medication when feasible, and using selective medical or surgical therapy for persistent or symptomatic disease. [1][2]
Diagnostic Confirmation and Red-Flag Exclusion
True gynecomastia involves glandular breast tissue. [2] Pseudogynecomastia involves adipose tissue without glandular proliferation. [2] Further evaluation is recommended when features suggest malignancy or an alternative diagnosis, including unilateral or rapidly progressive growth, a hard/fixed mass, skin changes, nipple discharge, or significant lymphadenopathy. [1][3] Initial evaluation should include a focused medication history that specifically assesses for drugs associated with gynecomastia, including spironolactone. [2][3]
Medication Review and Risk–Benefit Medication Modification
Spironolactone discontinuation or dose reduction is recommended when gynecomastia is clinically suspected to be drug-related and an alternative regimen is feasible. [1][2] Reversibility is more likely when treatment is started early after onset because longer-standing glandular tissue tends toward fibrosis. [1][2] In patients with heart failure treated with spironolactone in a randomized evaluation, gynecomastia occurred in approximately 9% of male participants at a mean dose of 26 mg daily. [4] A drug-induced gynecomastia systematic review found spironolactone to be associated with an increased risk of gynecomastia. [5]
Expected Course After Offending Drug Withdrawal
Gynecomastia associated with reversible etiologies may improve after removal of the causative factor. [1][2] Persistent symptoms after an adequate period off the offending agent support consideration of additional medical therapy or procedural management. [1][2]
Pharmacologic Therapy for Symptomatic or Early Disease
Selective estrogen receptor modulators are commonly used for painful or early gynecomastia when glandular proliferation persists despite addressing the cause. [1][2] Medical therapy selection is typically influenced by symptom severity, duration of gynecomastia, and contraindications. [1]
Treatment of Persistent, Fibrotic, or Long-Standing Gynecomastia
Surgical therapy is favored when gynecomastia persists despite medical management, when fibrosis is established, or when symptoms and cosmetic concerns remain significant. [1][6] Procedural options include gland-directed surgery and, when appropriate, contouring of residual fat. [6]
Targets for Follow-Up and Referral
Referral for specialist evaluation is recommended when malignancy cannot be excluded or when atypical features are present. [1][3] Follow-up is recommended to document changes in size and pain after medication modification and to reassess for progression. [1][2]
Common Pitfalls to Avoid
Failure to distinguish gynecomastia from pseudogynecomastia delays appropriate management and may lead to unnecessary workup or inappropriate treatment selection. [2] Missing malignancy red flags can delay diagnosis. [1][3] Continuing an offending antiandrogen medication without reassessing feasibility of dose reduction or substitution can prevent resolution. [1][2] Delaying intervention until glandular fibrosis develops reduces the likelihood of symptom improvement with non-surgical strategies. [1][2]
Practical Medication-Specific Approach for Spironolactone
Medication change feasibility should be assessed because spironolactone is a strong drug-associated cause of gynecomastia. [2] Dose reduction or discontinuation is recommended when clinically safe, and reassessment should be performed after a reasonable period to determine whether regression occurs. [1][2] Persistent painful glandular tissue after addressing spironolactone should be managed with appropriate medical therapy targeted to early disease biology or referred for surgical management in long-standing disease. [1][6] Endocrine and imaging evaluation should be pursued when clinical features are atypical or malignancy cannot be excluded. [1][3]